CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 623 enrolled
Drug / intervention
MTZ 500 mg twice daily x 7 days +1 moredrug
Likely dose
MTZ 500 mg twice daily x 7 daysfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01832480
NCT01832480Phase 3Completed
CompareCT.gov

Trichomonas Vaginalis Repeat Infections Among HIV Negative Women

Tulane University Health Sciences Center·interventional·Posted Apr 16, 2013·Updated Feb 12, 2019

In Brief

A Phase 3 clinical trial evaluating MTZ 500 mg twice daily x 7 days and MTZ 2 g for Vaginitis Trichomonal or Due to Trichomonas. Completed, enrolled 623 participants across 3 sites.

Detailed Summary

The overall goal of this project is to determine the influence of patient treatment and host factors on repeat Trichomonas vaginalis (TV) infections among HIV-negative women

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaginitis Trichomonal or Due to Trichomonas
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2013
Enrollment StartOct 6, 2014
Primary CompletionJun 5, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 13.2 years ago

Interventions

MTZ 500 mg twice daily x 7 daysdrug

MTZ 500 mg twice daily x 7 days

MTZ 2 gdrug

MTZ 2 g